Monday, October 26, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· June 11, 2026

Aduro Clean Technologies gibt Ausgabepreis für ein garantiertes öffentliches Emissionsangebot in Höhe von 15,64 Millionen US-Dollar sowie eine gleichzeitige Privatplatzierung von bis zu 7,17 Millionen US-Dollar bekannt

View original at globenewswire.com
Aduro Clean Technologies gibt Ausgabepreis für ein garantiertes öffentliches Emissionsangebot in Höhe von 15,64 Millionen US-Dollar sowie eine gleichzeitige Privatplatzierung von bis zu 7,17 Millionen US-Dollar bekannt LONDON, Ontario, June 11, 2026 (GLOBE NEWSWIRE) -- Aduro Clean Technologies Inc…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The public offering is not conditional on completion of the LIFE offering, and the LIFE offering is not conditional on completion of the public offering.

    60% confidence
  • Aduro's Hydrochemolytic™ technology uses water as the primary active ingredient in a chemical platform that operates at relatively low temperatures and costs.

    60% confidence
  • The company anticipates that certain insiders may participate in the LIFE offering, constituting a 'related party transaction' under MI 61-101, but expects to rely on exemptions from formal valuation and minority shareholder approval requirements as insider participation is not expected to exceed 25% of the company's market capitalization.

    60% confidence
  • The LIFE offering is expected to close on or about the closing date or another date determined by the company, but no later than 45 days after the date of this press release. The LIFE offering may close in one or more tranches.

    60% confidence
  • Aduro intends to use net proceeds from the offering for planning, development, and construction of the world's first industrial-scale FOAK demonstration facility, ongoing R&D expenses, and remaining amounts for general corporate purposes and working capital.

    60% confidence
  • The company intends to rely on the exemption under Section 602.1 of the TSX Company Manual, which provides that the TSX does not apply its standards to certain transactions involving eligible issuers listed on a recognized exchange.

    60% confidence
  • The public offering is expected to close on or about June 11, 2026, subject to satisfaction of customary closing conditions, including listing of offered shares on the TSX and Nasdaq and receipt of all required TSX and Nasdaq approvals.

    60% confidence

Data points we hold from this source

Aduro Clean Technologies Inc. · gross proceeds life offering7169810 USD
Aduro Clean Technologies Inc. · gross proceeds public offering15635404 USD
Aduro Clean Technologies Inc. · shares offered public1028645 shares
Aduro Clean Technologies Inc. · shares offered life private placement471698 shares
Aduro Clean Technologies Inc. · offer price usd15.20 USD_per_share
Aduro Clean Technologies Inc. · offer price cad21.20 CAD_per_share
Aduro Clean Technologies Inc. · gross proceeds total combined22805214 USD
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com
Aduro Clean Technologies gibt Ausgabepreis für ein garantiertes öffentliches Emissionsangebot in Höhe von 15,64 Millionen US-Dollar sowie eine gleichzeitige Privatplatzierung von bis zu 7,17 Millionen US-Dollar bekannt — Source | Via News | ViaNews Market